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Abstract
Background: Health care expenditures for older adults are disproportionately high and increasing
at both the individual and population levels. We evaluated the effects of the three cognitive training
interventions (memory, reasoning, or speed of processing) in the ACTIVE study on changes in
predicted medical care expenditures.
Methods: ACTIVE was a multisite randomized controlled trial of older adults (³ 65). Five-year
follow-up data were available for 1,804 of the 2,802 participants. Propensity score weighting was
used to adjust for potential attrition bias. Changes in predicted annualmedical expenditures were
calculated at the first and fifth annual follow-up assessments using a new method for translating
functional status scores. Multiple linear regression methods were used in this cost-offset analysis.
Results: At one and five years post-training, annual predicted expenditures declinedby $223 (p =
.024) and $128 (p = .309), respectively, in the speed of processing treatment group, but there were
no statistically significant changes in the memory or reasoning treatment groups compared to the
no-contact control group at either period. Statistical adjustment for age, race, education, MMSE
scores, ADL and IADL performance scores, EPT scores, chronic condition counts, and the SF-36
PCS and MCS scores at baseline did not alter the one-year ($244; p = .012) or five-year ($143; p
= .250) expenditure declines in the speed of processing treatment group.
Conclusion:  The speed of processing intervention significantly reduced subsequent annual
predicted medical care expenditures at the one-year post-baseline comparison, but annual savings
were no longer statistically significant at the five-year post-baseline comparison.
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Background
It is well known that medical expenditures for older adults
in the U.S. are disproportionately high, and continue to
increase at the individual and population levels [1,2]. A
growing literature has shown that the onset of cognitive
limitations in older adults, especially as they affect activity
of daily living (ADL) and instrumental ADL (IADL) per-
formance, is associated with increased health services use
and medical expenditures [3-6]. Based on cross-sectional
and longitudinal studies, we have suggested that at the
beginning of this process, when cognitive declines are first
detected, there is an increase in both physician and hospi-
tal use as part of the normal clinical diagnostic and evalu-
ation process [7-10]. But once a dementia diagnosis has
been reached, the triage and selection processes are
invoked. As a result, those with cognitive limitations
choose themselves, or through their families or physi-
cians, to forgo treatment [7-10]. Subsequent work by
other investigators has supported our interpretation [11-
14].
Based in part on this literature, the National Institutes of
Health (NIH) funded the Advanced Cognitive Training
for Independent and Vital Elderly (ACTIVE) multisite
study. ACTIVE was a randomized controlled trial (RCT) to
test the effectiveness and durability of three distinct cogni-
tive interventions in improving proximal outcomes (rea-
soning, memory, and processing speed), primary
outcomes (everyday problem solving, ADLs and IADLs,
and everyday speed), and secondary outcomes (health-
related quality of life [HRQoL], health services use, and
health care expenditures) [15].
Although all three ACTIVE treatments have been shown to
be effective at improving their targeted abilities (proximal
outcomes) at post-test, the speed of processing training
group demonstrated the largest gains, with 87% of partic-
ipants showing reliable improvement after the interven-
tion [16]. Furthermore, while each intervention
continued to show improvements in their targeted cogni-
tive abilities relative to baseline at both two- and five-year
follow-ups the greatest relative improvements in targeted
abilities were clearly associated with the speed of process-
ing group [16,17]. Indeed, the effect sizes at all time
points for the speed of processing group were more than
double those associated with the other interventions.
Statistically and clinically significant effects of ACTIVE's
speed of processing intervention have also been shown on
many of the secondary or health outcomes, relative to the
no-contact control group, including: (1) a 38% reduction
in the risk of global decline in HRQoL at two-years post-
baseline (p = .004), and a 25.6% reduction in the risk of
global decline in HRQoL (p < .038) at five-years post-
baseline [18,19]; (2) a 30% reduction in the risk of wors-
ening depressive symptoms at both one-year (p = .012)
and five-years (p = .023) post-baseline [20]; (3) a 38%
reduction in the risk of the onset of suspected clinical
depression at one-year (p < .01) post baseline [21]; (4)
improvements in self-rated health at two-, three-, and five-
years equivalent to at least half of the difference between
"excellent" and "very good" responses (p values < .05),
which is known to be associated with a 0.8% absolutere-
duction in the five-year mortality rate, and a 10% relative
mortality reduction (Wolinsky FD, Mahncke HW, Vander
Weg MW, Martin R, Unverzagt FW, Ball KK, Jones R,
Tennstedt SL, Speed of processing training improves self-
rated health in older adults: enduring effects observed in
the multi-site ACTIVE study, submitted); and, (5) a 64%
greater likelihood (p < .05) of improvements in internal
locus of control at five-years post-baseline (Wolinsky FD,
Vander Weg MW, Martin R, Unverzagt FW, Willis SL, Mar-
siske M, Rebok GW, Morris JN, Ball KK, Tennstedt SL,
Cognitive training improves internal locus of control
among older adults, submitted).
In this article, we extend the focus on secondary outcomes
by translating patient-reported outcomes into meaningful
variations in cost estimates appropriate for consideration
by diverse health care delivery stakeholders. Ideally, this
would be done using actual Medicare and other payor
claims. At the present time, however, we do not have
access to Medicare claims for the entire follow-up period,
nor to other payor claims at all. Therefore, we use knowl-
edge from empirical data showing the relationship
between functional status and medical expenditures to
translate changes over time in SF-36 composite scores into
predicted annual medical expenditure savings [22].
Methods
Design
A detailed description of ACTIVE is available elsewhere
[15]. Here we present sufficient information for back-
ground purposes. ACTIVE was a multisite, single-blind
RCT with three treatment arms and a no-contact control
group. It was hypothesized that each of the three interven-
tion arms would have a direct effect on its targeted,
trained outcome (proximal outcomes), and nonspecific
effects on each of its non-targeted, untrained outcomes. It
was further hypothesized that the effects of the ACTIVE
interventions on both the primary and secondary out-
comes would be mediated through the targeted, trained
(proximal) outcomes. Among the primary outcomes, the
reasoning and memory interventions were expected to
affect only everyday problem solving and ADLs and
IADLs, whereas the speed of processing intervention was
hypothesized to have more diverse effects, including ADLs
and IADLs, everyday speed, and driving habits. All threeBMC Health Services Research 2009, 9:109 http://www.biomedcentral.com/1472-6963/9/109
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ACTIVE interventions were expected to affect the second-
ary outcomes, including HRQoL, mobility, health services
use and expenditures.
The Original ACTIVE Sample
Although all ACTIVE study participants were at risk for
loss of functional independence, they had to live in the
community independent of formal care and be 65 years
old or older. Each of six sites used slightly different recruit-
ment strategies to identify 4,970 potential participants
from March 1998 through October 1999 [15]. Of these,
905 (18.1%) were excluded if they demonstrated cogni-
tive impairment (a Mini-Mental Status Examination
[MMSE; 23] score < 23), had corrected vision less than 20/
50, were dependent in hygiene, bathing or dressing, had
ever been diagnosed as having Alzheimer's Disease or had
had a stroke during the prior year, reported limited life
expectancy due to cancer or were undergoing chemother-
apy or radiation treatment at baseline, had difficulty com-
municating, planned on moving within one year,
anticipated having scheduling conflicts, or had previously
undergone cognitive training. Another 1,263 potential
participants (25.3%) refused to participate in either the
screening or enrollment processes. The 2,802 remaining
potential participants were screened, enrolled, and rand-
omized.
Interventions
Each of the three interventions involved ten sessions that
shared key elements, and involved 1-hour sessions. The
ten sessions were spread over six weeks, with an average
group size of 3–4 participants per group. Strategy instruc-
tion and practice exercises were the focus of the first five
intervention sessions, while the last five provided addi-
tional practice. Both the laboratory-type and everyday
activities used were well-specified in trainer manuals, and
the intervention trainers underwent extensive training,
certification, and continuous quality improvement evalu-
ation and review [15]. The focus of the reasoning training
was on inductive reasoning, especially the ability to solve
problems that followed a serial pattern and were manifest
in executive functioning. The focus of the memory training
was on verbal episodic memory, especially using mne-
monic strategies for remembering lists, sequences of
items, text material, and main ideas and story details. The
focus of the speed training was on visual search and the
ability to identify and locate visual information in a
divided attention format.
Booster Sessions
About one month prior to the first and third annual fol-
low-ups, booster training was offered to a 60% random
sample of cognitive intervention participants who had
completed at least 80% of the initial training sessions.
These participants received up to four additional stand-
ardized sessions at each of those two follow-ups under
equivalent circumstances. Because the method of select-
ing participants to receive booster training was condi-
tioned (i.e., dependent) on participant adherence, we do
not consider the booster effect in our analyses. That is, we
estimate a pooled effect within each of the three interven-
tion groups that reflects both those who were and were
not invited to participate in the booster sessions. The
assumption underlying this approach is that all trained
participants received the booster training, and that there
was no effect of booster training in those not actually
receiving booster training. This assumption biases our
results towards the null, and is overly conservative
because 89% of persons who were not randomized to
booster training were eligible for booster training. Eligibil-
ity for booster training did not significantly differ by train-
ing group.
Predicted Medical Expenditures
We have previously shown significant effects of the cogni-
tive interventions on clinically important differences in
HRQoL with the widely used eight SF-36 scales [24-30] at
both two and five years post-training [18,19]. Here we use
a method recently developed by an investigative team
from the Agency for Healthcare Research and Quality
(AHRQ), the University of Chicago, and QualityMetric
[22] for expressing observed changes in the overall Physi-
cal Composite Scores (PCS) and Mental Composite Scores
(MCS) of either the SF-12 or the SF-36 into changes in pre-
dicted annual medical expenditures from baseline to the
one-year follow-up, and from the third-year to the fifth-
year follow-up. Detailed descriptions and procedures for
using and scoring the SF-36, and the exact wording of the
SF-36 items are available elsewhere [24-30]. Scores on the
PCS and MCS theoretically range from 0 (worst health) to
100 (best health).
This new method was developed and validated using
5,542 participants from the 2000–2001 population-
based, nationally-representative Medical Expenditure
Panel Study (MEPS) sponsored by AHRQ to chart expend-
iture trends in the US. In their new approach, Fleishman
et al. used SF-12 scores to predict mean monthly expendi-
tures over the next year that were obtained from linked
administrative claims data [22]. Using Poisson regression,
their most sophisticated model (Model 6 in their Table
Four [22]) included age, gender, demographics, medical
conditions, the PCS and MCS scores, and prior health
expenditures; it explained 29.2% of the variance in actual
medical expenditures, which is relatively robust in the
expenditures literature [20]. Because unlike MEPS,
ACTIVE was an RCT, we begin with Fleishman et al.'s base
model (Model 1 in their Table Four [22]) which only
includes age, gender, and the PCS and MCS scores, and
explained 13.4% of the variance in actual medical expen-BMC Health Services Research 2009, 9:109 http://www.biomedcentral.com/1472-6963/9/109
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ditures. Our justification is that in the ACTIVE RCT we
may expect, and have previously shown, equivalence on
nearly all observed factors across treatment groups at
baseline [16-19]).
Because all ACTIVE participants were 65 years old or older
at baseline, the equation for predicted annual medical
care expenditure then becomes:
where male and age65 are binary markers for being a man
(vs. a woman) and being 65 years old or older (vs. being
younger), and male_age65  is the simple multiplicative
interaction term reflecting older men. The exponent (of
the bracketed, i.e., [x]) value is taken to yield dollar values,
because the coefficients shown are the un-exponentiated
Poisson regression coefficients obtained by Fleishman et
al [22]. The exponentiated value is then multiplied by 12
to obtain the estimate of predicted annual medical expen-
ditures, because the Fleishman et al.'s original equation
was for monthly expenditures [22]. Finally, to obtain a
differences in differences (or change) analysis, we sub-
tracted the annual expenditure estimate obtained at base-
line from the annual expenditure estimate obtained at the
one-year follow-up, and we subtracted the annual expend-
iture estimate obtained at the three-year follow up
(because there was no four-year follow-up) from the
annual expenditure estimate obtained at the five-year fol-
low-up.
As an added safeguard to the analysis of the base model
described above, we used multiple linear regression to sta-
tistically adjust the effects of treatment group first for age,
race, education, MMSE scores [23], ADL performance
[31], IADL performance [32], everyday cognitive perform-
ance scores [33], and medical conditions [34], and then
for baseline PCS and MCS scores [29,30] as well. Thus,
our final analysis considers all of the factors in Fleishman
et al.'s final model (i.e., Model 6 in their Table Four [24])
except for prior observed expenditures, which we do not
have in ACTIVE.
Analytic Sample
Of the 2,802 participants who were screened, enrolled,
and randomized, 1,804 (64.4%) were successfully reas-
sessed on all outcomes at the fifth annual follow-up. We
restrict our analysis to these 1,804 participants, regardless
of group assignment, treatment adherence, or booster sta-
tus, for two reasons. First, doing so maintains complete
comparability to our prior reports [19]. Second, this
approach avoids compositional change issues in compar-
ing the one-year and five-year results. Attrition was not
associated with treatment status [18,19].
Attrition Bias
Our focus on the 1,804 (64.4%) of the 2,802 original
ACTIVE participants who were reassessed on the HRQoL
outcomes at the five-year follow-up raises the potential for
attrition bias in relation to outcomes of interest. There-
fore, as in our prior reports, propensity score methods
were used to adjust for potential attrition bias [35-37]. We
estimated a multivariable logistic regression model of
whether outcome data were available at the five-year fol-
low-up, and computed the predicted probabilities of
inclusion in the analytic sample. The propensity score
model has previously been reported [19]. This model
included binary indicators for each of the three cognitive
intervention arms, and baseline age, sex, race, MMSE
scores, ADLs, IADLs, EPT scores, depressive symptoms,
comorbid medical conditions, and SF-36 scores. We then
determined the average participation rate (i.e., whether
five-year follow-up data were available, or P) within each
propensity score (predicted probability) quintile, and
used the inverse (1/P) to weight the data. This gives
greater influence to retained participants who were most
like those not followed. Finally, the propensity score
weights were adjusted so that the weighted N was 1,804
(equal to the number of participants actually reassessed at
the five year follow-up).
Results
Descriptive
Table 1 contains the unadjusted or crude means or per-
centages for the variables of interest in the analytic sample
using the propensity score weighted data overall, and by
treatment group. Overall, at baseline the mean age was
75.7, 25% were men, 31% were Black, and the average
educational attainment was 13.4 years. The mean MMSE
[23] score was 27.2, the average score on the Minimum
Data Set (MDS) ADL performance scale [31] was 0.3
(observed range = 0 to 10), the average score on the MDS
IADL performance scale [32] was 4.2 (observed range = 0
to 23), the average score on the EPT [33] was 18.3, and the
mean number of chronic conditions [34] was 2.3. At base-
line, the mean PCS score was 42.3, the mean MCS score
was 53.6, and the average predicted annual medical
expenditure was $6,741. The only statistically significant
difference across treatment groups in these baseline varia-
bles involved the MCS score, which ranged from a low of
52.7 in the reasoning group to a high of 54.4 in the no-
contact control group. From baseline to the first annual
follow-up the speed of processing group showed a mean
MCS score improvement (0.982), although this was mar-
ginally insignificant (p = .100). From the third to the fifth
annual follow-up the speed of processing group again
showed a mean MCS score improvement (0.701) that was
statistically significant (p = .009). Note that the compari-
sons shown in Table 1, however, are not adjusted for any
of the covariates shown in that table.
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Multiple Linear Regression
In contrast to the baseline findings shown in Table 1, both
predicted annual medical expenses at the first annual fol-
low-up as well as the change in those predicted expendi-
tures since baseline were statistically significantly different
across the treatment groups. Overall, predicted annual
medical expenses rose from baseline to the first annual
follow-up by $78.34, resulting in annual predicted
expenses of $6,929. But there was considerable variation
across treatment groups. Tables 2 and 3, contain the par-
tial, unstandardized (B) coefficients obtained from the
three-step multiple linear regression of the changes in pre-
dicted annual medical expenditures clarifies the pattern in
the variation. Note that the reference group in all models
Table 1: Unadjusted Baseline and Follow-Up Means or Percentages among the ACTIVE Participants (Weighted N = 1,804) in the 
Analytic Sample, by Treatment Group.
Variable Memory Group
(N = 444)
Reasoning Group
(N = 447)
Speed of Processing
Group (N = 452)
Control Group
(N = 462)
Total
Baseline
Age (years) 75.8 76.0 75.2 75.9 75.7
Men (%) 24.8 26.3 24.8 25.3 25.3
Black (%) 29.1 30.4 33.4 32.3 31.4
Education (years) 13.5 13.3 13.5 13.4 13.4
MMSE (score) 27.2 27.1 27.2 27.2 27.2
ADL Count* 0.42 0.31 0.26 0.31 0.32
IADL Count 4.16 4.26 4.11 4.16 4.17
EPT Score 18.67 17.98 18.35 18.31 18.33
Medical Cond. Count 2.3 2.4 2.4 2.2 2.3
PCS Score 42.68 41.16 42.93 42.31 42.27
MCS Score* 54.26 52.71 53.22 54.38 53.65
Predicted Annual Medical 
Expenditures
6,469 7,163 6,576 6,756 6,741
Changes in SF-36 Composite 
Scores
PCS (baseline to 1 year) -.556 -.452 -.129 -.450 -.399
MCS (baseline to 1 year) -.408 -.033 .982 .314 .208
PCS (3 to 5 years)** -.313 .221 -.680 .168 -.151
MCS (3 to 5 years)** .224 -.648 .701 -1.198 -.231
Predicted Annual Medical 
Expenditure Changes
Baseline to 1 year* 146.65 199.31 -130.59 91.96 78.34
3 to 5 years 229.12 234.90 73.99 202.00 184.76
Notes: The analytic sample was restricted to ACTIVE participants successfully re-interviewed at the fifth annual follow-up, with propensity score 
weighting used to adjust for potential attrition bias, in order to avoid compositional incomparability to our prior report [19]. MMSE = mini-mental 
status exam; ADL = activities of daily living; IADL = instrumental ADLs; EPT = everyday performance test; and, PCS = physical component score; 
MCS = mental component score.
* = p < .05; ** = p < .01
Table 2: Partial, Unstandardized (B) Coefficients (Dollar Values) Obtained from Three-Step Multiple Linear Regression Models of the 
Changes in Predicted Annual Medical Expenditures at the One-Year Annual Follow-Up among the ACTIVE Participants (Weighted N 
= 1,804) in the Analytic Sample.
Treatment Group Change in Expenditures at the First 
Annual Follow-up
Change in Expenditures at the First 
Annual Follow-up
Change in Expenditures at the First 
Annual Follow-up
Step One Step Two Step Three
Memory 54.70 80.66 69.29
Reasoning 107.35 121.23 121.22
Speed of Processing -222.55* -215.49* -243.99*
Notes: The analytic sample was restricted to ACTIVE participants successfully re-interviewed at the fifth annual follow-up, with propensity score 
weighting used to adjust for potential attrition bias, in order to avoid compositional incomparability to our prior report [19]. Step one includes the 
three treatment group variables. Step two includes the three treatment group variables, and age, race, education, MMSE, ADLs, IADLs, EPT scores, 
and medical conditions. Step three includes the three treatment group variables, age, race, education, MMSE, ADLs, IADLs, EPT scores, and medical 
conditions, as well as the baseline PCS and MCS scores. The control group is the omitted or reference category.
* = p < .05BMC Health Services Research 2009, 9:109 http://www.biomedcentral.com/1472-6963/9/109
Page 6 of 9
(page number not for citation purposes)
shown in Tables 2 (baseline to first annual follow-up) and
3 (third annual to fifth annual follow-ups) is the no-con-
tact control group.
The only statistically significant effects are shown in Table
2 for the one-year follow-up was for the speed of process-
ing treatment group. In terms of changes in predicted
expenditures, these data show that there was a statistically
significant decline in annual predicted medical expendi-
tures from baseline to the first annual follow-up of
$222.55 (p = .024) for the speed of processing group, and
that further statistical adjustment for age, race, education,
MMSE scores, ADLs, IADLs, EPT scores, and medical con-
ditions (i.e, step two), as well as the baseline PCS and
MCS scores (i.e., step three) did not alter this effect. The
effects in the memory and reasoning treatment groups
were not statistically significant in this comparison. As
shown in Table 3, from the third annual follow-up to the
fifth annual follow-up, although the decline in annual
predicted medical expenditures for the speed of process-
ing group continued, it was notably smaller and no longer
statistically significant ($128.01; p = .309). Again, the
effects in the memory and reasoning treatment groups
were not statistically significant in this comparison.
Discussion
Summary
Our cost-offset analyses have shown significant differ-
ences by treatment intervention group in annual pre-
dicted medical expenditures from baseline to the one-year
follow-up. Those differences were driven by the lower pre-
dicted expenditures observed among participants in the
speed of processing treatment group. When compared to
the control group, those differences amounted to pre-
dicted annual savings of $223 or $215 or $244, depend-
ing on whether the treatment effects were unadjusted, or
adjusted for age, race, education, MMSE scores, ADLs,
IADLs, and the EPT scores, or adjusted for those factors as
well as the baseline PCS and MCS scores, respectively. By
the end of the five year follow-up period, however, the
annual difference in predicted medical expenditures had
notably diminished and was no longer statistically signif-
icant.
Importance
These results are especially important for three reasons.
First, ACTIVE is the largest multisite RCT ever conducted
that focused on improving or maintaining cognitive per-
formance among older adults [15], which enhances both
ACTIVE's internal and external validity. Second, the pre-
dicted expenditures in the ACTIVE sample are reasonably
representative of the Medicare population. This is
reflected in the fact that the first annual follow-up per cap-
ita predicted annual expenditures for ACTIVE ($6,929)
were comparable to the national per capita base (i.e., age
³ 65) average annual estimate for older adults in 2003
under the applicable Medicare Advantage (MA) capitation
rate structure ($6,638) [38]. Finally, the speed of process-
ing intervention is computer-based, designed to be self-
administered, and could allow participants to proceed at
her/his own pace, thus increasing the likelihood that max-
imal effective dosing is delivered. At the same time, how-
ever, our results are not particularly surprising, because
the estimated expenditures are ultimately just a retransfor-
mation of the original SF-36 data which we had used in
prior analyses [18,19]. That said, our approach does pro-
vide meaningful variations in cost estimates appropriate
for consideration by diverse health care delivery stake-
holders.
Limitations
Our study is not without limitations. The most important
of these is our reliance on the new method [22] to predict
annual medical expenditures. Under ideal circumstances,
Table 3: Partial, Unstandardized (B) Coefficients (Dollar Values) Obtained from Three-Step Multiple Linear Regression Models of the 
Changes in Predicted Annual Medical Expenditures at the Five-Year Annual Follow-Up among the ACTIVE Participants (Weighted N 
= 1,804) in the Analytic Sample.
Treatment Group Change in Expenditures at the Fifth 
Annual Follow-up
Change in Expenditures at the Fifth 
Annual Follow-up
Change in Expenditures at the Fifth 
Annual Follow-up
Step One Step Two Step Three
Memory 27.12 58.66 44.58
Reasoning 32.90 23.99 42.75
Speed of Processing -128.01 -123.96 -143.02
Notes: The analytic sample was restricted to ACTIVE participants successfully re-interviewed at the fifth annual follow-up, with propensity score 
weighting used to adjust for potential attrition bias, in order to avoid compositional incomparability to our prior report [19]. Step one includes the 
three treatment group variables. Step two includes the three treatment group variables, and age, race, education, MMSE, ADLs, IADLs, EPT scores, 
and medical conditions. Step three includes the three treatment group variables, age, race, education, MMSE, ADLs, IADLs, EPT scores, and medical 
conditions, as well as the baseline PCS and MCS scores. The control group is the omitted or reference category.
* = p < .05BMC Health Services Research 2009, 9:109 http://www.biomedcentral.com/1472-6963/9/109
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we would involve used actual administrative claims data
files. Unfortunately, we do not have Medicare claims for
the entire follow-up period, and we do not have any other
payor claims at all. Particularly relevant in this population
are costs for services such as homemaker and meals that
enable and support independent living for which claims
are not available. Accordingly, further research that exam-
ines actual expenditure savings to Medicare and other pay-
ors over this period is necessary to verify the predicted
expenditure savings reported here. It is also important to
note that we did not use a smearing estimator [39,40] in
the process of generating the predicted expenditure esti-
mates [22], and as a result, our standard errors may have
been underestimated after exponentiation of the logged
estimates to transform them back into dollars. In sensitiv-
ity analyses (not shown), however, we replicated our anal-
yses using the logged estimates themselves, and found
robust results with equivalent effect sizes and significance
levels. Thus, it is unlikely that underestimation of the
standard errors is problematic.
Policy Relevance
Our results have significant health policy relevance. The
speed of processing intervention was able to reduce pre-
dicted medical expenditures by 3.2% ($223/$6,929)
between baseline and the first annual follow-up. Moreo-
ver, we emphasize here the fact that ACTIVE participants
were only allowed ten 1-hour training sessions at base-
line, unless they had been randomized, conditioned upon
completing at least 8 of the ten baseline intervention ses-
sions, to receive up to four additional standardized ses-
sions one-month prior to the first and third annual
follow-ups. Because the receipt of booster training was
conditioned on participant adherence, however, we can-
not address the "dosing" question (i.e., the separation of
the basic intervention effect [up to 10 hours] from the
booster effect [up to 8 additional hours for those so rand-
omized]) in an intent-to-treat format. Nonetheless, when
we have explored the "dosing" issue from an effectiveness
standpoint for other outcomes, the results have been what
one would expect–greater effects for those randomized to
basic and booster speed of processing training, than for
those randomized to just basic speed of processing
(Wolinsky FD, et al., Speed of processing training
improves self-rated health in older adults: enduring effects
observed in the multi-site ACTIVE study, submitted;
(Wolinsky FD, et al., Cognitive training improves internal
locus of control among older adults, submitted).
How Speed of Processing Works
At this point, it is important to raise, if not address, the
ultimate question–how did the speed of processing inter-
vention reduce predicted expenditures? As we have noted
before, speed of processing operates through sensory-
motor elaboration and repetition [15-19], and procedural
tasks have a broader pattern of regional brain activation
than explicit memory tasks [41]. We believe that the
resulting improvements in brain activation and/or struc-
ture delayed the onset or reduced the risk of cognitive
slowing, which has been argued to be among the most sig-
nificant contributors to overall cognitive decline [42,43].
That said, we conducted additional (ad hoc) analyses to
determine whether the effect of speed of processing on
predicted medical expenditures was direct, indirect, or
both. First, we calculated the baseline to one-year follow-
up improvement in processing speed. In our analytic sam-
ple overall, there was an average improvement (reduc-
tion) in processing time on the Useful Field of Vision
(UFOV) test [15-17] of 156 milliseconds (ms; standard
deviation = 211 ms), with the improvements in the mem-
ory, reasoning, and no-contact control groups ranging
from 98 to 101 ms, vs. an average improvement in the
speed of processing group of 321 ms (p < .0001). Thus,
random assignment to the speed of processing interven-
tion resulted in a net UFOV test improvement of about
220 ms more than any other group, a differential effect
size of about 1.0. This was expected, because the UFOV
test was the proximal target outcome for the speed of
processing intervention.
We then added the one-year improvement in the UFOV
test to the model reflected in column two (i.e., change in
expenditures at the first annual follow-up) of Table 2.
Doing so did not appreciably alter the effects for the mem-
ory or reasoning groups, which remained statistically
insignificant (p > .40). The effect for the speed of process-
ing group, however, increased to a $295.39 medical
expenditure reduction (p = .016), and the effect for UFOV
test improvement was a $0.44 lower medical expenditure
per ms of improvement in processing speed (p = .033).
The standardized regression coefficients for these effects
were fundamentally equivalent (i.e., -0.089 vs. -0.067,
respectively). On the one hand, this indicates that random
assignment to the speed of processing intervention group
reduced predicted medical care expenditures, and that the
greater the improvement in processing speed, the greater
the reduction in predicted medical expenses. To the best
of our knowledge, this is the first demonstration that
improvements in processing speed transfer to distal
health outcomes. On the other hand, it indicates that the
etiologic mechanism here is not just direct, because for
that to have been the case, the effect of random assign-
ment to the speed of processing group should have been
dramatically reduced and no longer statistically signifi-
cant. Thus, speed of processing has both direct and indi-
rect effects on predicted medical expenditures. Further
research will be needed to identify the causal pathways
involved in those indirect effects.BMC Health Services Research 2009, 9:109 http://www.biomedcentral.com/1472-6963/9/109
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Conclusion
The speed of processing intervention significantly reduced
subsequent annual predicted medical care expenditures at
the one-year post-baseline comparison, but annual sav-
ings were no longer statistically significant at the five-year
post-baseline comparison. This is not surprising because
the 1-year follow-up analysis would best showcase the
potential effects of the ACTIVE cognitive interventions on
predicted medical expenditures. The reason is that each of
the three ACTIVE interventions involved a rather low dose
and rather short duration, and therefore their effects
would be most observable at 1-year post-baseline.
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